Ravi A. Madan, M.D.

Ravi A. Madan, M.D.
Associate Research Physician
Genitourinary Malignancies Branch
Clinical Director, Genitourinary Malignancies Branch

Team Member of:

William L. Dahut, M.D.

Dr. Madan is the clinical director of the Genitourinary Malignancies Branch. His clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.

Areas of Expertise
immunotherapy, prostate cancer, therapeutic cancer vaccines, immune check point inhibitors, metastatic prostate cancer, medullary thyroid cancer

Contact Info

Ravi A. Madan, M.D.
Center for Cancer Research
National Cancer Institute
10/13N240B
Bethesda, MD 20892
Ph: 301-480-7168
Fax: 301-480-8867
madanr@mail.nih.gov
Get Vcard
Permalink

Selected Publications

  1. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
    Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.
    Clin. Cancer Res.. 14: 4526-31, 2008. [ Journal Article ]
  2. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
    Lancet Oncol.. 13: 501-8, 2012. [ Journal Article ]
  3. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
    Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
    Cancer Immunol. Immunother.. 63: 225-34, 2014. [ Journal Article ]
  4. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
    Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
    Cancer Immunol. Immunother.. 59: 663-74, 2010. [ Journal Article ]
  5. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
    Madan RA, Gulley JL, Fojo T, Dahut WL.
    Oncologist. 15: 969-75, 2010. [ Journal Article ]

Dr. Madan is an Assistant Clinical Investigator at the National Cancer Institute (NCI), conducting clinical research in therapeutic cancer vaccines and genitourinary malignancies. Dr. Madan received his M.D. from the UMDNJ-New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. He currently holds a joint appointment in the Medical Oncology Branch and the Laboratory of Tumor Immunology and Biology. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.

Name Position
Sheri McMahon R.N., B.S.N. Nurse Specialist